Form 4: Aprea Therapeutics Director Marc Duey Buys Shares
SEC Form 4 Filing
Director Marc Duey acquired 190 shares of Aprea Therapeutics at $2.58 per share on October 14, 2024.
Summary
- On October 14, 2024, Marc Duey, a director of Aprea Therapeutics, Inc., purchased 190 shares of common stock at a price of $2.58 per share.
- Following this transaction, Mr. Duey directly owns 210,113 shares of Aprea Therapeutics common stock.
- Mr. Duey also indirectly owns 602 shares through his spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares can be seen as a vote of confidence, but the small number of shares purchased limits the impact on sentiment.
Positives
- The director's purchase could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as it can provide insights into management's view of the company's valuation and prospects. However, it's just one data point and should be considered alongside other factors.
Stakeholder Impact
- The purchase may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/14/2024 | Date of transaction: Marc Duey purchased 190 shares of Aprea Therapeutics common stock. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.